Geneva, May 4 -- International Clinical Trials Registry received information related to the study (ChiCTR2600123198) titled 'Ongericimab Injection Reducing Recurrence of ischemic Stroke' on April 22.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: Beijing Tiantan Hospital, Capital Medical University
Condition:
Cerebrovascular disease
Intervention:
High target group:Receiving standardized lipid-lowering treatment to achieve an LDL-C reduction target below 70 mg/dL (1.8 mmol/L)
Recruitment Status: Not Recruiting
Phase: 3
Date of First Enrollment: 2026-04-22
Target Sample Size: High target group:2405;Low target group:2405;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn...